Jazz Pharmaceuticals (JAZZ) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Jazz Pharmaceuticals (NASDAQ: JAZZ):

• 10/8/2026 – Jazz Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $299.00 to $296.00. They now have an “outperform” rating on the stock.
• 10/7/2026 – Jazz Pharmaceuticals had its price target raised by Truist Financial Corporation from $281.00 to $286.00. They now have a “buy” rating on the stock.
• 10/3/2026 – Jazz Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 9/30/2026 – Jazz Pharmaceuticals is now covered by Citigroup Inc.. They set a “buy” rating and a $325.00 price target on the stock.
• 9/24/2026 – Jazz Pharmaceuticals is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $337.00 price target on the stock.
• 9/24/2026 – Jazz Pharmaceuticals is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $337.00 price target on the stock.
• 9/11/2026 – Jazz Pharmaceuticals had its price target raised by UBS Group AG from $315.00 to $337.00. They now have a “buy” rating on the stock.
• 9/10/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $270.00 to $271.00. They now have an “overweight” rating on the stock.
• 8/28/2026 – Jazz Pharmaceuticals was given a new $299.00 price target by Royal Bank Of Canada.
• 8/26/2026 – Jazz Pharmaceuticals had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $277.00 price target on the stock.
• 8/26/2026 – Jazz Pharmaceuticals had its price target raised by Morgan Stanley from $283.00 to $322.00. They now have an “overweight” rating on the stock.
• 8/26/2026 – Jazz Pharmaceuticals was given a new $300.00 price target by Canaccord Genuity Group Inc..
• 8/26/2026 – Jazz Pharmaceuticals had its price target raised by Deutsche Bank Aktiengesellschaft from $287.00 to $300.00. They now have a “buy” rating on the stock.
• 8/26/2026 – Jazz Pharmaceuticals had its price target raised by Truist Financial Corporation from $264.00 to $281.00. They now have a “buy” rating on the stock.
• 8/26/2026 – Jazz Pharmaceuticals had its price target raised by Needham & Company LLC from $292.00 to $310.00. They now have a “buy” rating on the stock.

Insider Activity

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $230.33, for a total value of $1,381,980.00. Following the completion of the transaction, the director owned 345,875 shares of the company’s stock, valued at approximately $79,665,388.75. The trade was a 1.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $240.94, for a total transaction of $289,128.00. Following the completion of the transaction, the executive vice president owned 47,671 shares of the company’s stock, valued at approximately $11,485,850.74. This trade represents a 2.46% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 100,121 shares of company stock valued at $24,855,802. 4.10% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.